Anna Rubartelli Selected Research

Therapeutics

10/2022	Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment.
1/2020	Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.
1/2018	Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis.
9/2017	Restoring microenvironmental redox and pH homeostasis inhibits neoplastic cell growth and migration: therapeutic efficacy of esomeprazole plus sulfasalazine on 3-MCA-induced sarcoma.
1/2017	The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.
3/2014	Inflammation, DAMPs, tumor development, and progression: a vicious circle orchestrated by redox signaling.
3/2013	The pharmacologic inhibition of the xc- antioxidant system improves the antitumor efficacy of COX inhibitors in the in vivo model of 3-MCA tumorigenesis.
11/2011	The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets.
10/2011	TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death.
5/2007	Masquerader: high mobility group box-1 and cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anna Rubartelli Research Topics

Disease

22	Inflammation (Inflammations) 10/2022 - 10/2002
15	Neoplasms (Cancer) 01/2022 - 03/2002
5	Cryopyrin-Associated Periodic Syndromes 01/2020 - 09/2007
3	Fever (Fevers) 01/2024 - 02/2014
3	Autoimmune Diseases (Autoimmune Disease) 10/2023 - 06/2004
3	Melanoma (Melanoma, Malignant) 09/2017 - 05/2007
3	Carcinoma (Carcinomatosis) 10/2008 - 04/2002
2	Amyloid Plaque 01/2020 - 01/2019
2	Sepsis (Septicemia) 01/2020 - 05/2007
2	Sarcoma (Soft Tissue Sarcoma) 09/2017 - 03/2013
2	Arthritis (Polyarthritis) 01/2016 - 05/2007
2	Necrosis 10/2010 - 10/2009
1	Communicable Diseases (Infectious Diseases) 10/2023
1	Critical Illness (Critically Ill) 10/2022
1	COVID-19 10/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Fibrosis (Cirrhosis) 01/2021
1	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 01/2021
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2021
1	Muscular Dystrophies (Muscular Dystrophy) 01/2021
1	Neuroblastoma 12/2020
1	Amyloidosis 01/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020
1	Atherosclerosis 01/2019
1	Rheumatoid Arthritis 01/2018
1	Fibrosarcoma 01/2017
1	Starvation 01/2017
1	Pyogenic arthritis, pyoderma gangrenosum, and acne 01/2016
1	Pyoderma Gangrenosum 01/2016
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2016
1	Acne Vulgaris 01/2016
1	Simian Acquired Immunodeficiency Syndrome 11/2015
1	Familial Mediterranean Fever (Periodic Disease) 02/2014
1	Carcinogenesis 03/2013

Drug/Important Bio-Agent (IBA)

11	CytokinesIBA 01/2023 - 07/2005
9	HMGB1 Protein (HMG1)IBA 01/2021 - 10/2002
7	AntioxidantsIBA 10/2023 - 10/2008
7	Proteins (Proteins, Gene)FDA Link 10/2022 - 04/2002
6	InterleukinsIBA 01/2020 - 10/2002
5	InflammasomesIBA 01/2024 - 12/2011
5	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2023 - 11/2011
5	Interleukin-18 (Interleukin 18)IBA 01/2020 - 04/2002
3	NLR ProteinsIBA 10/2022 - 05/2010
3	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 10/2022 - 09/2007
3	ThioredoxinsIBA 01/2020 - 10/2008
3	Interleukin-1 (Interleukin 1)IBA 01/2016 - 09/2007
3	Messenger RNA (mRNA)IBA 01/2008 - 04/2002
2	Sulfhydryl Compounds (Thiols)IBA 10/2023 - 10/2008
2	Protons (Proton)IBA 01/2022 - 09/2017
2	AlarminsIBA 01/2021 - 03/2014
2	Protein Isoforms (Isoforms)IBA 01/2021 - 09/2004
2	Immunoglobulin FragmentsIBA 01/2020 - 01/2017
2	Proton Pump InhibitorsIBA 01/2020 - 09/2017
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 09/2017 - 03/2013
2	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2017 - 11/2015
2	NucleotidesIBA 01/2016 - 01/2008
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 09/2012 - 09/2007
2	Cysteine (L-Cysteine)FDA Link 11/2011 - 10/2008
2	Interleukin-1beta (Interleukin 1 beta)IBA 09/2007 - 06/2004
2	Adenosine Triphosphate (ATP)IBA 04/2006 - 10/2002
1	PyrinIBA 01/2024
1	Colchicine FDA LinkGeneric 01/2024
1	Oxidants (Oxidizing Agents)IBA 10/2023
1	Oxygen (Dioxygen)IBA 10/2023
1	AutoantibodiesIBA 01/2023
1	Hormones (Hormone)IBA 01/2022
1	AntibodiesIBA 01/2021
1	Liposomes (Liposome)IBA 12/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	EnzymesIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2020
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2019
1	LipidsIBA 01/2019
1	dapansutrileIBA 01/2018
1	NitrilesIBA 01/2018
1	Therapeutic UsesIBA 09/2017
1	Adenosine Triphosphatases (ATPase)IBA 09/2017
1	MethylcholanthreneIBA 09/2017
1	Esomeprazole (Nexium)FDA Link 09/2017
1	Explosive Agents (Explosives)IBA 01/2017
1	Fibronectins (Fibronectin)IBA 01/2017
1	Melphalan (Alkeran)FDA LinkGeneric 01/2017
1	Mutant Proteins (Protein, Mutant)IBA 01/2017
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 01/2016
1	Proline (L-Proline)FDA Link 01/2016
1	Leucine (L-Leucine)FDA Link 01/2016
1	VaccinesIBA 10/2014
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 03/2013
1	Ibuprofen (Motrin)FDA LinkGeneric 03/2013
1	3- mercapto- 3,3- cyclopentamethylenepropionic acidIBA 03/2013
1	LipopolysaccharidesIBA 09/2012
1	Interleukin-6 (Interleukin 6)IBA 09/2012
1	Toll-Like Receptors (Toll-Like Receptor)IBA 09/2012
1	Toll-Like Receptor AgonistsIBA 09/2012
1	Aligeron (AS 2)IBA 11/2011
1	Cystine (L-Cystine)IBA 11/2011

Therapy/Procedure

10	Therapeutics 10/2022 - 05/2007
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2020
1	Immunotherapy 01/2020